Triethyl-3-phenyl-propionylorthoformat | 34736-83-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Triethyl-3-phenyl-propionylorthoformat
• 英文别名: 3-phenyl-orthopropionic acid triethyl ester；3-Phenyl-orthopropionsaeure-triaethylester；(3,3,3-triethoxy-propyl)-benzene；(3,3,3-Triethoxypropyl)benzene；3,3,3-triethoxypropylbenzene
• CAS: 34736-83-9
• 化学式: C₁₅H₂₄O₃
• 分子量: 252.354
• InChiKey: XVAWRKNJMRHNCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Triethyl-3-phenyl-propionylorthoformat 在 aluminum tri-tert-butoxide 作用下， 生成 1,1-二乙氧基-3-苯基丙-1-烯
  参考文献：
  名称：

  Ketene Acetals. XXIX. The Mechanism of the Reaction of Ketene Acetal with Various Halides

  摘要：

  DOI：

  10.1021/ja01130a057
• 作为产物：
  描述：

  苯代丙腈 在 盐酸 作用下， 生成 Triethyl-3-phenyl-propionylorthoformat
  参考文献：
  名称：

  Ketene Acetals. XXIX. The Mechanism of the Reaction of Ketene Acetal with Various Halides

  摘要：

  DOI：

  10.1021/ja01130a057

文献信息

• [EN] PURIN-6-ONE-DERIVATIVES<br/>[FR] DERIVES DE PURINE-6-ONE
  申请人：ALTANA PHARMA AG

  公开号：WO2004089953A1

  公开（公告）日：2004-10-21

  The compounds of a certain formula (I) in which e.g. R2, R3, R4 and R5 have the meanings as given below are novel effective PDE2 inhibitors. R2 is hydrogen, 1-4C-alkyl, 1-hydroxy-2-4C-alkyl, 1-4C-alkylcarbonyl or 1-(acetyloxy)-2-4C-alkyl and R3 is Arylbutyl, Heteroarylbutyl, Arylpropyl, Heteroarylpropyl, Arylethyl or Heteroarylethyl; wherein Aryl is phenyl, naphthalenyl or indanyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, Heteroaryl is pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolyl, isoquinolyl, naphthyridinyl, phthalazinyl, indolyl, isoindolyl, indazolyl, purinyl, pteridinyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl or thiophenyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, R4 is 1-4C-alkoxy which is completely or predominantly substituted by fluorine and R5 is halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1 -4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkylcarbonyloxy, 1-4C-alkylsulfonylamino, phenylcarbonylamino, phenylcarbonylamino substituted in the phenyl moiety by R6 and/or R7, benzylcarbonylamino, benzylcarbonylamino substituted in the phenyl moiety by R8 and/or R9, phenylsulfonylamino, phenylsulfonylamino substituted in the phenyl moiety by R10 and/or R11, benzylsulfonylamino or benzylsulfonylamino substituted in the phenyl moiety by R12 and/or R13.

  具有特定结构式（I）的化合物，其中例如R2、R3、R4和R5具有以下所述含义，是新颖的有效的PDE2抑制剂。R2为氢、1-4C-烷基、1-羟基-2-4C-烷基、1-4C-烷基羰基或1-(乙酰氧基)-2-4C-烷基，R3为芳基丁基、杂芳基丁基、芳基丙基、杂芳基丙基、芳基乙基或杂芳基乙基；其中芳基为苯基、萘基或茚基，每个基可选地最多被卤素、羟基、硝基、三氟甲基、羧基、1-4C-烷基、1-4C-烷氧基或1-4C-烷氧羰基取代最多三次，杂芳基为吡啶基、吡嗪基、吡啶嗪基、嘧啶基、喹唑啉基、喹喜啶基、茴啉基、喹啉基、异喹啉基、萘噻啉基、菲啉基、吲哚基、异吲哚基、吲唑基、嘌呤基、哌嗪基、苯并呋喃基、苯并噁唑基、苯并噻唑基、苯并咪唑基、噁唑基、异噁唑基、噻唑基、异噻唑基、咪唑基、吡咯基、吡唑基、呋喃基或噻吩基，每个基可选地最多被卤素、羟基、硝基、三氟甲基、羧基、1-4C-烷基、1-4C-烷氧基或1-4C-烷氧羰基取代最多三次，R4为完全或主要由氟取代的1-4C-烷氧基，R5为卤素、羟基、硝基、三氟甲基、羧基、1-4C-烷基、1-4C-烷氧基、完全或主要由氟取代的1-4C-烷氧基、1-4C-烷氧羰基、氨基、单或双1-4C-烷基氨基、氨基羰基、单或双1-4C-烷基氨基羰基、1-4C-烷基羰基氨基、1-4C-烷基羰基氧基、1-4C-烷基磺酰氨基、苯基羰基氨基、苯基羰基氨基在苯基上被R6和/或 R7取代、苄基羰基氨基、苄基羰基氨基在苯基上被R8和/或 R9取代、苯基磺酰氨基、苯基磺酰氨基在苯基上被R10和/或 R11取代、苄基磺酰氨基或苄基磺酰氨基在苯基上被R12和/或 R13取代。
• Purin-6-one-derivatives
  申请人：Bar Thomas

  公开号：US20060106037A1

  公开（公告）日：2006-05-18

  The compounds of a certain formula (I) in which e.g. R2, R3, R4 and R5 have the meanings as given below are novel effective PDE2 inhibitors. R2 is hydrogen, 1-4C-alkyl, 1-hydroxy-2-4C-alkyl, 1-4C-alkylcarbonyl or 1-(acetyloxy)-2-4C-alkyl and R3 is Arylbutyl, Heteroarylbutyl, Arylpropyl, Heteroarylpropyl, Arylethyl or Heteroarylethyl; wherein Aryl is phenyl, naphthalenyl or indanyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, Heteroaryl is pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, quinazolinyl, quinoxalinyl, cinnolinyl, quinolyl, isoquinolyl, naphthyridinyl, phthalazinyl, indolyl, isoindolyl, indazolyl, purinyl, pteridinyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl or thiophenyl, each of which optionally substituted up to three times identically or differently by halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy or 1-4C-alkoxycarbonyl, R4 is 1-4C-alkoxy which is completely or predominantly substituted by fluorine and R5 is halogen, hydroxyl, nitro, trifluoromethyl, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxy which is completely or predominantly substituted by fluorine, 1-4C-alkoxycarbonyl, amino, mono- or di-1-4C-alkylamino, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkylcarbonyloxy, 1-4C-alkylsulfonylamino, phenylcarbonylamino, phenylcarbonylamino substituted in the phenyl moiety by R6 and/or R7, benzylcarbonylamino, benzylcarbonylamino substituted in the phenyl moiety by R8 and/or R9, phenylsulfonylamino, phenylsulfonylamino substituted in the phenyl moiety by R10 and/or R11, benzylsulfonylamino or benzylsulfonylamino substituted in the phenyl moiety by R12 and/or R13.

  某种公式（I）的化合物具有以下含义的R2，R3，R4和R5，是新颖的有效PDE2抑制剂。其中，R2是氢，1-4C-烷基，1-羟基-2-4C-烷基，1-4C-烷基羰基或1-(乙酰氧基)-2-4C-烷基，R3是芳基丁基，杂芳基丁基，芳基丙基，杂芳基丙基，芳基乙基或杂芳基乙基；其中，芳基是苯基，萘基或茚基，每个芳基可选地被卤素，羟基，硝基，三氟甲基，羧基，1-4C-烷基，1-4C-烷氧基或1-4C-烷氧羰基等取代高达三次，杂芳基是吡啶基，吡嗪基，吡咯嗪基，嘧啶基，喹唑啉基，喹喔啉基，茚啉基，喹啉基，异喹啉基，萘啶基，邻苯二氮杂基，吲哚基，异吲哚基，吲唑基，嘧啶基，苯并呋喃基，苯并噁唑基，苯并噻唑基，苯并咪唑基，噁唑基，异噁唑基，噻唑基，异噻唑基，咪唑基，吡咯基，吡唑基，呋喃基或噻吩基，每个杂芳基可选地被卤素，羟基，硝基，三氟甲基，羧基，1-4C-烷基，1-4C-烷氧基或1-4C-烷氧羰基等取代高达三次，R4是完全或主要由氟取代的1-4C-烷氧基，R5是卤素，羟基，硝基，三氟甲基，羧基，1-4C-烷基，1-4C-烷氧基，完全或主要由氟取代的1-4C-烷氧基，1-4C-烷氧羰基，氨基，单或双1-4C-烷基氨基，氨基羰基，单或双1-4C-烷基氨基羰基，1-4C-烷基羰基氨基，1-4C-烷基羰氧基，1-4C-烷基磺酰氨基，苯基羰基氨基，在苯基中由R6和/或R7取代的苯基羰基氨基，苄基羰基氨基，在苯基中由R8和/或R9取代的苄基羰基氨基，苯基磺酰氨基，在苯基中由R10和/或R11取代的苯基磺酰氨基，苄基磺酰氨基或在苯基中由R12和/或R13取代的苄基磺酰氨基。
• Sah, Journal of the Chinese Chemical Society (Peking), 1933, vol. 1, p. 100,103
  作者：Sah

  DOI：——

  日期：——
• 4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: Novel antiarrhythmic agents
  作者：Robert E. Johnson、Eugene R. Baizman、Carolyn Becker、Eric A. Bohnet、Rebecca H. Bell、Nancy C. Birsner、Carl A. Busacca、Philip M. Carabateas、Christopher C. Chadwick

  DOI：10.1021/jm00074a017

  日期：1993.10

  A series of 4,5-dihydro-1-phenyl-1H-2,4-benzodiazepines has been identified as potential antiarrhythmic agents that interact with sodium and potassium channels and prolong the ventricular effective refractory period (ERP) in anesthetized guinea pigs. Concomitant displacement of radiolabeled bactrachotoxin from site II in Na+ channels and of radiolabeled dofetilide from delayed rectifier K+ channels was evident with all members of this chemical series at a concentration of 10 muM. Structure-activity relationship (SAR) studies using a paced guinea pig model to assess prolongation of the ERP indicated that methyl or ethyl at the 1-position had little effect on activity, while larger groups caused a diminution of activity. Compounds with substituents at either the 3- or 4-position that increased lipophilicity generally were more potent; however, too many lipophilic substituents simultaneously at positions 1, 3, and 4 resulted in less active compounds. Substituents on either aromatic ring had little influence on activity, and phenyl at the 5-position resulted in a significant reduction in antiarrhythmic activity. When two sets of enantiomerically pure compounds were tested in the guinea pig, chirality was shown to be important for activity of 8, where the (R)-enantiomer was the more active, but not in the case of 15, where the enantiomers were equiactive. Several compounds in this series increased the threshold for vertricular fibrillation and refractoriness in myocardially-infarcted anesthetized cata and delayed the onset of aconitine-induced arrhythmias in anesthetized guinea pigs following intravenous dosing. Moreover, these compounds possessed oral antiarrhythmic activity in conscious myocardially-infarcted dogs. Compound R-15 has been advanced for further biological and toxicological evaluations.
• Oishi,T. et al., Chemical and pharmaceutical bulletin, 1971, vol. 19, p. 1871 - 1875
  作者：Oishi,T. et al.

  DOI：——

  日期：——